Dose–Response Effect of Photobiomodulation Therapy on Muscle Performance and Fatigue During a Multiple-Set Knee Extension Exercise: A Randomized, Crossover, Double-Blind Placebo-Controlled Trial

Behavioral changes in irritability, restlessness, and sleep disturbance are associated with the ingestion of tartrazine in some children. A dose-response effect was observed.

Download Full-text

Synthetic food coloring and behavior: A dose response effect in a double-blind, placebo-controlled, repeated-measures study

The Journal of Pediatrics ◽

10.1016/s0022-3476(06)80164-2 ◽

1994 ◽

Vol 125 (5) ◽

pp. 691-698 ◽

Cited By ~ 133

Author(s):

Katherine S. Rowe ◽

Kenneth J. Rowe

Keyword(s):

Dose Response ◽

Repeated Measures ◽

Double Blind ◽

Double Blind Placebo ◽

Response Effect ◽

Dose Response Effect ◽

And Behavior

Download Full-text

Photobiomodulation Therapy Effects on Resistance Training Volume and Discomfort in Well-Trained Adults: A Randomized, Double-Blind, Placebo-Controlled Trial

Photobiomodulation Photomedicine and Laser Surgery ◽

10.1089/photob.2019.4777 ◽

2020 ◽

Vol 38 (12) ◽

pp. 720-726

Author(s):

Lucas B.R. Orssatto ◽

Mateus Rossato ◽

Monique Vargas ◽

Fernando Diefenthaeler ◽

Cíntia de la Rocha Freitas

Keyword(s):

Resistance Training ◽

Controlled Trial ◽

Photobiomodulation Therapy ◽

Training Volume ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2010.34.3178 ◽

2012 ◽

Vol 30 (4) ◽

pp. 362-371 ◽

Cited By ~ 153

Author(s):

Beth Y. Karlan ◽

Amit M. Oza ◽

Gary E. Richardson ◽

Diane M. Provencher ◽

Vincent L. Hansen ◽

...

Keyword(s):

Ovarian Cancer ◽

Dose Response ◽

Objective Response ◽

Recurrent Ovarian Cancer ◽

Weekly Paclitaxel ◽

Ca 125 ◽

Double Blind ◽

Response Effect ◽

Amg 386 ◽

Dose Response Effect

Purpose To estimate the efficacy and toxicity of AMG 386, an investigational peptide-Fc fusion protein that neutralizes the interaction between the Tie2 receptor and angiopoietin-1/2, plus weekly paclitaxel in patients with recurrent ovarian cancer. Patients and Methods Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer were randomly assigned 1:1:1 to receive paclitaxel (80 mg/m2 once weekly [QW], 3 weeks on/1 week off) plus intravenous AMG 386 10 mg/kg QW (arm A), AMG 386 3 mg/kg QW (arm B), or placebo QW (arm C). The primary end point was progression-free survival (PFS). Secondary end points included overall survival, objective response, CA-125 response, safety, and pharmacokinetics. Results One hundred sixty-one patients were randomly assigned. Median PFS was 7.2 months (95% CI, 5.3 to 8.1 months) in arm A, 5.7 months (95% CI, 4.6 to 8.0 months) in arm B, and 4.6 months (95% CI, 1.9 to 6.7 months) in arm C. The hazard ratio for arms A and B combined versus arm C was 0.76 (95% CI, 0.52 to 1.12; P = .165). Further analyses suggested an exploratory dose-response effect for PFS across arms (Tarone's test, P = .037). Objective response rates for arms A, B, and C were 37%, 19%, and 27%, respectively. The incidence of grade ≥ 3 adverse events (AEs) in arms A, B, and C was 65%, 55%, and 64%, respectively. Frequent AEs included hypertension (8%, 6%, and 5% in arms A, B, and C, respectively), peripheral edema (71%, 51%, and 22% in arms A, B, and C, respectively), and hypokalemia (21%, 15%, and 5% in arms A, B, and C, respectively). AMG 386 exhibited linear pharmacokinetic properties at the tested doses. Conclusion AMG 386 combined with weekly paclitaxel was tolerable, with a manageable and distinct toxicity profile. The data suggest evidence of antitumor activity and a dose-response effect, warranting further studies in ovarian cancer.

Download Full-text

Dose-response effect of photobiomodulation therapy on neuromuscular economy during submaximal running

Lasers in Medical Science ◽

10.1007/s10103-017-2378-4 ◽

2017 ◽

Vol 33 (2) ◽

pp. 329-336 ◽

Cited By ~ 9

Author(s):

Rodolfo André Dellagrana ◽

Mateus Rossato ◽

Raphael Luiz Sakugawa ◽

Caetano Decian Lazzari ◽

Bruno Manfredini Baroni ◽

...

Keyword(s):

Dose Response ◽

Photobiomodulation Therapy ◽

Response Effect ◽

Dose Response Effect

Download Full-text

Dose-Response Effect of Fruit and Vegetables on Insulin Resistance in People at High Risk of Cardiovascular Disease: A randomized controlled trial

Diabetes Care ◽

10.2337/dc13-0718 ◽

2013 ◽

Vol 36 (12) ◽

pp. 3888-3896 ◽

Cited By ~ 20

Author(s):

I. R. Wallace ◽

C. T. McEvoy ◽

S. J. Hunter ◽

L. L. Hamill ◽

C. N. Ennis ◽

...

Keyword(s):

Insulin Resistance ◽

Cardiovascular Disease ◽

Randomized Controlled Trial ◽

High Risk ◽

Dose Response ◽

Controlled Trial ◽

Fruit And Vegetables ◽

Response Effect ◽

Randomized Controlled ◽

Dose Response Effect

Download Full-text

Evaluation of Bacillus subtilis R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults

Beneficial Microbes ◽

10.3920/bm2014.0031 ◽

2015 ◽

Vol 6 (1) ◽

pp. 19-27 ◽

Cited By ~ 21

Author(s):

A. Hanifi ◽

T. Culpepper ◽

V. Mai ◽

A. Anand ◽

A.L. Ford ◽

...

Keyword(s):

Bacillus Subtilis ◽

Dose Response ◽

Rating Scale ◽

Controlled Trial ◽

Probiotic Strain ◽

Healthy Adults ◽

Double Blind ◽

Double Blind Placebo ◽

Gastrointestinal Symptom Rating Scale ◽

Gi Symptoms

A probiotic formulation of Enterococcus faecium R0026 and Bacillus subtilis R0179 has been evaluated in previous clinical trials. However, B. subtilis R0179 has not been evaluated as a single probiotic strain or in combination with other strains at doses higher than 0.1×109 cfu. To establish oral dose-response tolerance and gastrointestinal (GI) viability of B. subtilis R0179, a randomised, double-blind, placebo-controlled trial in healthy adults (n=81; 18-50 years old) was conducted. Participants received B. subtilis R0179 at 0.1, 1.0 or 10×109 cfu/capsule/day or placebo for four weeks. General wellness was assessed using a daily questionnaire evaluating GI, cephalic, ear-nose-throat, behavioural, emetic, and epidermal symptoms. GI symptoms were further evaluated using a weekly gastrointestinal symptom rating scale (GSRS). GI transit viability of B. subtilis R0179 was assessed by plating and microbiota analysis by 16S rRNA at baseline, week 4 of the intervention and washout. General wellness and GI function were not affected by oral consumption of B. subtilis R0179 at any dose. Daily questionnaire syndrome scores were not different from baseline and did not exceed a clinically significant score of 1. GSRS syndrome scores were not different from baseline and ranged from 1.1±0.1 to 1.9±0.2. Faecal viable counts of B. subtilis R0179 demonstrated a dose response: the placebo group (1.1±0.1 log10 cfu/g) differed from 0.1×109 (4.6±0.1 log10 cfu/g), 1×109 (5.6±0.1 log10 cfu/g) and 10×109 (6.4±0.1 log10 cfu/g) (P<0.0001). No significant changes in phyla were observed, but sequence reads binned to multiple operational taxonomic units matching closest to Ruminococci increased during probiotic supplementation. B. subtilis R0179 survives passage through the human GI tract and is well tolerated by healthy adults at intakes from 0.1 to 10×109 cfu/day. The trial has been registered at www.clinicaltrials.gov under NCT01802151.

Download Full-text